These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 10951705)

  • 1. [Chemotherapy in metastatic or recurrent endometrial carcinoma].
    Deppe G; Baumann P; Munkarah A
    Zentralbl Gynakol; 2000; 122(7):355-60. PubMed ID: 10951705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hormonal therapy and chemotherapy of endometrial cancer].
    Krauss T; Huschmand H; Hinney B; Viereck V; Emons G
    Zentralbl Gynakol; 2002 Jan; 124(1):45-50. PubMed ID: 11873314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatment options for endometrial cancer.
    Santin AD; Bellone S; O'Brien TJ; Pecorelli S; Cannon MJ; Roman JJ
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):679-89. PubMed ID: 15270671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
    Gadducci A; Cosio S; Genazzani AR
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
    McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
    Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
    Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
    Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of advanced-stage and recurrent endometrial cancer.
    Ray M; Fleming G
    Semin Oncol; 2009 Apr; 36(2):145-54. PubMed ID: 19332249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal treatment of endometrial cancer: past, present and future.
    Podczaski E; Mortel R
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):469-89. PubMed ID: 11476566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormonal therapy for endometrial adenocarcinoma].
    Susumu N; Aoki D; Suzuki N; Nozawa S
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):934-45. PubMed ID: 11478142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent outline of chemotherapy for uterine endometrial cancer].
    Watanabe Y; Hoshiai H
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():346-50. PubMed ID: 15535265
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
    Lupe K; D'Souza DP; Kwon JS; Radwan JS; Harle IA; Hammond JA; Carey MS
    Gynecol Oncol; 2009 Jul; 114(1):94-8. PubMed ID: 19406459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy in endometrial cancer.
    Obel JC; Friberg G; Fleming GF
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):459-68. PubMed ID: 16981669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.
    Hogberg T
    Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):463-9. PubMed ID: 18467080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
    Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of endometrial cancer.
    Barrena Medel NI; Bansal S; Miller DS; Wright JD; Herzog TJ
    Expert Opin Pharmacother; 2009 Aug; 10(12):1939-51. PubMed ID: 19586421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of leuprolide in advanced/recurrent endometrial cancer.
    Covens A; Thomas G; Shaw P; Ackerman I; Osborne R; Lukka H; Carey M; Franssen E; Roche K
    Gynecol Oncol; 1997 Jan; 64(1):126-9. PubMed ID: 8995560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic therapy for recurrent endometrial cancer: a review of North American trials.
    Dellinger TH; Monk BJ
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):905-16. PubMed ID: 19589030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data.
    Polyzos NP; Pavlidis N; Paraskevaidis E; Ioannidis JP
    Eur J Cancer; 2006 Feb; 42(3):319-26. PubMed ID: 16376072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for high-risk early-stage endometrial cancer.
    Kodama J; Seki N; Hiramatsu Y
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):42-7. PubMed ID: 17218851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
    Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.